Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141726 · ClinicalTrials.gov registry record · Phase 2
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00141726 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 34 participants.
The verdict
NCT00141726, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of etanercept in the treatment of patients with sub-acute lung injury following a bone marrow transplant. This study will also examine the toxicity of treatment with etanercept as well as whether there is an improved quality of life in these patients.
Interventions
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2003-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141726
The ClinicalTrials.gov registry entry for NCT00141726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etanercept is the first listed.
NCT00141726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00141726 about?
NCT00141726 is a clinical study titled "Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant". The purpose of this study is to determine the effectiveness of etanercept in the treatment of patients with sub-acute lung injury following a bone marrow transplant. This study will also examine the toxicity of treatment with etanercept as well as whether there is an improved quality of life in thes...
What is the current status of trial NCT00141726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2003-10. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00141726?
The interventions under investigation include: Etanercept (DRUG).
Who is sponsoring clinical trial NCT00141726?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.